These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

282 related articles for article (PubMed ID: 24745923)

  • 21. Place in therapy of anti-IL-17 and 23 in psoriasis according to the severity of comorbidities: a focus on cardiovascular disease and metabolic syndrome.
    Trovato E; Rubegni P; Prignano F
    Expert Opin Biol Ther; 2022 Dec; 22(12):1443-1448. PubMed ID: 35726639
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Meta-analysis of psoriasis, cardiovascular disease, and associated risk factors.
    Miller IM; Ellervik C; Yazdanyar S; Jemec GB
    J Am Acad Dermatol; 2013 Dec; 69(6):1014-24. PubMed ID: 24238156
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Psoriasis in 2016 : Co-morbidities and therapeutic update].
    Daoud M; Benhadou F; Willaert F
    Rev Med Brux; 2016; 37(4):205-209. PubMed ID: 28525217
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical aspects and comorbidities of psoriasis.
    Ayala F; Ayala F
    J Rheumatol Suppl; 2009 Aug; 83():19-20. PubMed ID: 19661531
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prevalence of metabolic syndrome in patients with psoriasis: a hospital-based case-control study.
    Gisondi P; Tessari G; Conti A; Piaserico S; Schianchi S; Peserico A; Giannetti A; Girolomoni G
    Br J Dermatol; 2007 Jul; 157(1):68-73. PubMed ID: 17553036
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comorbidities in psoriasis patients.
    Kim N; Thrash B; Menter A
    Semin Cutan Med Surg; 2010 Mar; 29(1):10-5. PubMed ID: 20430302
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Metabolic syndrome and non-cardiac vascular diseases: an update from human studies.
    Katsiki N; Athyros VG; Karagiannis A; Mikhailidis DP
    Curr Pharm Des; 2014; 20(31):4944-52. PubMed ID: 24320038
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Endothelial dysfunction and the effects of TNF inhibitors on the endothelium in psoriasis and psoriatic arthritis: a systematic review.
    Brezinski EA; Follansbee MR; Armstrong EJ; Armstrong AW
    Curr Pharm Des; 2014; 20(4):513-28. PubMed ID: 23565632
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Psoriasis and cardiovascular disease: the elusive link.
    Manolis AA; Manolis TA; Melita H; Manolis AS
    Int Rev Immunol; 2019; 38(1):33-54. PubMed ID: 30457023
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Psoriasis comorbidities.
    Gottlieb AB; Chao C; Dann F
    J Dermatolog Treat; 2008; 19(1):5-21. PubMed ID: 18273720
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Common and Not-So-Common Comorbidities of Psoriasis.
    Menter MA; Armstrong AW; Gordon KB; Wu JJ
    Semin Cutan Med Surg; 2018 Feb; 37(2S):S48-S51. PubMed ID: 29614138
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Psoriasis and the metabolic syndrome.
    Gisondi P; Fostini AC; Fossà I; Girolomoni G; Targher G
    Clin Dermatol; 2018; 36(1):21-28. PubMed ID: 29241748
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cardiometabolic Comorbidities in Psoriasis and Psoriatic Arthritis.
    Puig L
    Int J Mol Sci; 2017 Dec; 19(1):. PubMed ID: 29295598
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Assessor-blinded study of the metabolic syndrome and surrogate markers of increased cardiovascular risk in children with moderate-to-severe psoriasis compared with age-matched population of children with warts.
    Volf EM; Levine DE; Michelon MA; Au SC; Patvardhan E; Dumont N; Loo DS; Kuvin J; Gottlieb AB
    J Drugs Dermatol; 2011 Aug; 10(8):900-1. PubMed ID: 21818512
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Management of moderate to severe psoriasis in patients with metabolic comorbidities.
    Gisondi P; Galvan A; Idolazzi L; Girolomoni G
    Front Med (Lausanne); 2015; 2():1. PubMed ID: 25654080
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Psoriasis and atherothrombotic diseases: disease-specific and non-disease-specific risk factors.
    Gisondi P; Girolomoni G
    Semin Thromb Hemost; 2009 Apr; 35(3):313-24. PubMed ID: 19452407
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Immune-mediated inflammatory diseases and other comorbidities in patients with psoriasis: baseline characteristics of patients in the AQUILES study.
    Vanaclocha F; Crespo-Erchiga V; Jiménez-Puya R; Puig L; Sánchez-Carazo JL; Ferrán M; Sancho C; Juliá B; Cea-Calvo L; Marín-Jiménez I; García-Vicuña R;
    Actas Dermosifiliogr; 2015; 106(1):35-43. PubMed ID: 25091923
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The role of statins in the treatment of type 2 diabetes mellitus: an update.
    Katsiki N; Athyros VG; Karagiannis A; Mikhailidis DP
    Curr Pharm Des; 2014; 20(22):3665-74. PubMed ID: 24040875
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Psoriasis as initiator or amplifier of the systemic inflammatory march: impact on development of severe vascular events and implications for treatment strategy.
    Su YS; Yu HS; Li WC; Ko YC; Chen GS; Wu CS; Lu YW; Yang YH; Lan CC
    J Eur Acad Dermatol Venereol; 2013 Jul; 27(7):876-83. PubMed ID: 22702656
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Psoriasis and cardiovascular disorders.
    Frieder J; Ryan C
    G Ital Dermatol Venereol; 2016 Dec; 151(6):678-693. PubMed ID: 27627099
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.